Search results for "Prophylaxi"

showing 10 items of 182 documents

Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adeniti…

2023

ObjectiveTo evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction.Patients and methodsThe medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00 ± 7.00 months in the period b…

International Registry PFAPA syndrome Streptococcus salivarius K12 autoinflammatory disease probiotic prophylaxis tonsillitisSettore MED/38 - Pediatria Generale E SpecialisticaAutoinflammationGeneral MedicineHuman medicinePFAPA syndromeFrontiers in Medicine
researchProduct

European expert opinion on the management of invasive candidiasis in adults

2011

Item does not contain fulltext This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad ans…

Invasive mycoses and compromised host Translational research [N4i 2]AdultMicrobiology (medical)medicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentPlacebo-controlled studyMEDLINEInvasive mycoses and compromised host Infection and autoimmunity [N4i 2]MicrobiologyMedicineHumanscandidaemiaCandidiasis InvasiveguidelinesIntensive care medicineWatchful Waitingtherapybusiness.industryTreatment optionsPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]General MedicineInvasive candidiasisComparative trialAntibiotic Prophylaxismedicine.diseaseOptimal managementEuropeIntensive Care UnitsInfectious DiseasesconsensusExpert opinioncandidabusinessWatchful waitingClinical Microbiology and Infection
researchProduct

Méthodes alternatives de lutte contre les maladies des plantes

2003

LUTTE CONTRE LES MALADIESPROPHYLAXIE[SDV.BV.PEP] Life Sciences [q-bio]/Vegetal Biology/Phytopathology and phytopharmacy[SDV.BV.PEP]Life Sciences [q-bio]/Vegetal Biology/Phytopathology and phytopharmacy
researchProduct

Supplemental Perioperative Oxygen and the Risk of Surgical Wound Infection: A Randomized Controlled Trial

2006

ABSTRACT Three hundred patients were enrolled in a double-blind, randomized, controlled study designed to investigate the ability of supplemental perioperative oxygen to reduce wound infection. Participants were age 18 to 80 years, had no coexisting serious medical conditions, and were scheduled to undergo elective colorectal surgery at one of 14 participating hospitals in Spain. No patients undergoing minor or laparoscopic surgery were included. Anesthesia and antibiotic prophylaxis were standardized for the study. Patients were randomized by computer-generated codes to receive an oxygen/air mixture of 30% or 80% fraction of inspired oxygen (F102) intraoperatively and postoperatively for 6…

Laparoscopic surgerymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentObstetrics and GynecologySurgical woundGeneral MedicinePerioperativeColorectal surgerySurgerylaw.inventionRandomized controlled triallawFraction of inspired oxygenRelative riskmedicineAntibiotic prophylaxisbusinessObstetrical & Gynecological Survey
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct

Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

2017

This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox re…

Lung DiseasesMaleOncologylung diseaseAntifungal AgentsSkin Neoplasmsmedicine.medical_treatment030230 surgeryTHERAPY030207 dermatology & venereal diseases0302 clinical medicinelung transplantation/pulmonologypatient safetyEPIDEMIOLOGYMedicineImmunology and AllergyPharmacology (medical)malignant [complication]RISKHazard ratioImmunosuppressionMiddle AgedPrognosisinfection and infectious agents - fungalPRACTICE GUIDELINEScomplication: malignantCarcinoma Squamous Cellantifungal [antibiotic]FemaleLung Transplantationmedicine.drugCohort studyAdultmedicine.medical_specialtyAdolescentinfectious diseaseSOCIETYANTIFUNGAL PROPHYLAXISclinical research/practiceArticleYoung Adult03 medical and health sciencesantibiotic: antifungal; clinical research/practice; complication: malignant; health services and outcomes research; infection and infectious agents - fungal; infectious disease; lung disease; lung transplantation/pulmonology; patient safety; Immunology and Allergy; Transplantation; Pharmacology (medical)LONG-TERM VORICONAZOLEInternal medicineHumansLung transplantationEXPOSUREAgedRetrospective StudiesVoriconazoleTransplantationSKIN-CANCERbusiness.industryProportional hazards modelRetrospective cohort studyantibiotic: antifungalhealth services and outcomes researchTransplant RecipientsSurgeryTransplantationRECIPIENTSVoriconazolebusinessFollow-Up Studies
researchProduct

Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort study

2018

BACKGROUND: Invasive aspergillosis (IA) is a frequent complication in lung transplant recipients (LTRs). Clinical risk factors for IA have not been fully characterized, especially in the era of extensive anti-fungal prophylaxis. The primary objective of this study was to evaluate the clinical risk factors associated with IA in LTRs. The secondary objective was to assess the mortality in LTRs who had at least 1 episode of IA compared with LTRs who never had experienced IA.METHODS: We conducted an international, multicenter, retrospective cohort study of 900 consecutive adults who received lung transplants between 2005 and 2008 with 4years of follow-up. Risk factors associated with IA were id…

Male0301 basic medicineAntifungal Agentsviruses030230 surgeryAspergillosisanti-fungal prophylaxis; Aspergillus spp; invasive aspergillosis; lung transplant recipient; single-lung transplant; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationCohort StudiesPostoperative Complications0302 clinical medicineRisk Factorshemic and lymphatic diseasesMedicineInvasive Pulmonary AspergillosisFirst episodeMortality rateHazard ratioMiddle Agedembryonic structuresFemaleCardiology and Cardiovascular MedicineLung TransplantationCohort studyAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyanimal structuresAdolescent030106 microbiologyYoung Adult03 medical and health sciencesanti-fungal prophylaxisInternal medicineHumansIntensive care medicineAgedProportional Hazards ModelsRetrospective Studiesinvasive aspergillosisTransplantationbusiness.industryProportional hazards modelAspergillus fumigatusAspergillus spp anti-fungal prophylaxis invasive aspergillosis lung transplant recipient single-lung transplantAspergillus sppRetrospective cohort studybiochemical phenomena metabolism and nutritionmedicine.diseaseSurvival Analysissingle-lung transplantTransplantationSurgerybusinesslung transplant recipientFollow-Up StudiesThe Journal of Heart and Lung Transplantation
researchProduct

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

2018

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline up…

MaleAftercare32 Biomedical and Clinical SciencesLanadelumabC1-inhibitorDiseaseGuidelineRecommendations0302 clinical medicinePregnancyDiagnosisImmunology and Allergy030212 general & internal medicinePrecision MedicineChildHereditary angioedemaConsensus conferenceSelf-administrationManagementGRADEHereditary angioedemaFemaleComplement C1 Inhibitor ProteinQuality of lifeAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyWhat treatmentConsensusAdolescentHealth Planning GuidelinesImmunologyMEDLINEDysfunctional family7.3 Management and decision makingYoung Adult03 medical and health sciencesRare DiseasesQuality of life (healthcare)Clinical ResearchTerminology as TopicIndividualized therapymedicineHumansLactationFinal versionProphylaxisbusiness.industryPreventionAngioedemas HereditaryGuidelinePrecision medicinemedicine.disease3211 Oncology and Carcinogenesis030228 respiratory systemFamily medicineTherapybusiness7 Management of diseases and conditions
researchProduct

Antibiotic prophylaxis in patients who had undergone to prostate biopsy in between the EMA warning era: effects of fluoroquinolones in diabetic and n…

2022

Abstract Purpose To investigate the effects of different antibiotic prophylaxis regimens in patients with diabetes mellitus (DM) candidates to trans-rectal ultrasound-guided prostate biopsy (TRUSPB). Methods 143 outpatients with DM who underwent TRUSPB during the period 2018–2020 were selected from a cohort of 1150 patients in 3 different institutions. Exclusion criteria were allergies, concomitant anti-platelet therapies and uncontrolled DM. Different antibiotic prophylaxis regimens were adopted. Bacterial resistance levels to fluoroquinolones into the different communities were also collected. Univariable and multivariable binomial logistic regression analyses were used to assess the odds…

MaleAntibiotic resistanceUrologyBiopsyProstateRectumBacterial InfectionsAntibiotic ProphylaxisProstate biopsyAnti-Bacterial AgentsFluoroquinoloneAntibiotic prophylaxiDiabetes MellitusHumansAntibiotic prophylaxis; Antibiotic resistance; Fluoroquinolones; Infection; Prostate biopsyInfectionFluoroquinolonesWorld journal of urology
researchProduct

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct